A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Phase of Trial: Phase III
Latest Information Update: 01 Apr 2017
At a glance
- Drugs Sucroferric oxyhydroxide (Primary) ; Sevelamer
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Sponsors Kissei Pharmaceutical
- 10 Jun 2017 Biomarkers information updated
- 01 Apr 2017 Primary endpoint (Serum phosphate concentrations) has been met, according to results published in the Nephrology.
- 01 Apr 2017 Results published in the Nephrology.